Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.

about

Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.

Item

http://www.wikidata.org/entity/Q41925040

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Self-limited membranous nephro ...... -related macular degeneration.

@en

type

Item

label

Self-limited membranous nephro ...... -related macular degeneration.

@en

prefLabel

Self-limited membranous nephro ...... -related macular degeneration.

@en

P1476

Self-limited membranous nephro ...... -related macular degeneration.

@en

P2093

Ahmad Al-Taee

http://www.w3.org/2001/XMLSchema#string

Gebran Khneizer

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.

Bevacizumab increases risk for severe proteinuria in cancer patients.

Vascular endothelial growth factor: basic science and clinical progress.

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Bevacizumab (Avastin) for the treatment of ocular disease.

Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database.

Favorable clinical course of patients experiencing bevacizumab-induced proteinuria.

P304

134-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.15171/JNP.2017.23

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bahar Bastani

P577

2017-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975092

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5607973

http://www.w3.org/2001/XMLSchema#string